Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1985 May;75(5):1702–1712. doi: 10.1172/JCI111879

Mechanism of action of gemfibrozil on lipoprotein metabolism.

K Saku, P S Gartside, B A Hynd, M L Kashyap
PMCID: PMC425514  PMID: 3923042

Abstract

Gemfibrozil is a potent lipid regulating drug whose major effects are to increase plasma high density lipoproteins (HDL) and to decrease plasma triglycerides (TG) in a wide variety of primary and secondary dyslipoproteinemias. Its mechanism of action is not clear. Six patients with primary familial endogenous hypertriglyceridemia with fasting chylomicronemia (type V lipoprotein phenotype) with concurrent subnormal HDL cholesterol levels (HDL deficiency) were treated initially by diet and once stabilized, were given gemfibrozil (1,200 mg/d). Each patient was admitted to the Clinical Research Center with metabolic kitchen facilities, for investigation of HDL and TG metabolism immediately before and after 8 wk of gemfibrozil treatment. Gemfibrozil significantly increased plasma HDL cholesterol, apolipoprotein (apo) AI, and apo AII by 36%, 29%, and 38% from base line, respectively. Plasma TG decreased by 54%. Kinetics of apo AI and apo AII metabolism were assessed by analysis of the specific radioactivity decay curves after injection of autologous HDL labeled with 125I. Gemfibrozil increased synthetic rates of apo AI and apo AII by 27% and 34%, respectively, without changing the fractional catabolic rates. Stimulation of apo AI and apo AII synthesis by gemfibrozil was associated with the appearance in plasma of smaller (and heavier) HDL particles as assessed by gradient gel electrophoresis and HDL composition. Postheparin extra-hepatic lipoprotein lipase activity increased significantly by 25% after gemfibrozil, and was associated with the appearance in plasma of smaller very low density lipoprotein particles whose apo CIII:CII ratio was decreased. These data suggest that gemfibrozil increases plasma HDL levels by stimulating their synthesis. Increased transport (turnover) of HDL induced by gemfibrozil may be significant in increasing tissue cholesterol removal in these patients.

Full text

PDF
1702

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson D. W., Nichols A. V., Forte T. M., Lindgren F. T. Particle distribution of human serum high density lipoproteins. Biochim Biophys Acta. 1977 Jul 22;493(1):55–68. doi: 10.1016/0005-2795(77)90259-8. [DOI] [PubMed] [Google Scholar]
  2. BARTLETT G. R. Phosphorus assay in column chromatography. J Biol Chem. 1959 Mar;234(3):466–468. [PubMed] [Google Scholar]
  3. Bilheimer D. W., Eisenberg S., Levy R. I. The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. Biochim Biophys Acta. 1972 Feb 21;260(2):212–221. doi: 10.1016/0005-2760(72)90034-3. [DOI] [PubMed] [Google Scholar]
  4. Blanche P. J., Gong E. L., Forte T. M., Nichols A. V. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta. 1981 Sep 24;665(3):408–419. doi: 10.1016/0005-2760(81)90253-8. [DOI] [PubMed] [Google Scholar]
  5. Blum C. B., Levy R. I., Eisenberg S., Hall M., 3rd, Goebel R. H., Berman M. High density lipoprotein metabolism in man. J Clin Invest. 1977 Oct;60(4):795–807. doi: 10.1172/JCI108833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Brensike J. F., Levy R. I., Kelsey S. F., Passamani E. R., Richardson J. M., Loh I. K., Stone N. J., Aldrich R. F., Battaglini J. W., Moriarty D. J. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984 Feb;69(2):313–324. doi: 10.1161/01.cir.69.2.313. [DOI] [PubMed] [Google Scholar]
  7. Brown W. V., Baginsky M. L. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun. 1972 Jan 31;46(2):375–382. doi: 10.1016/s0006-291x(72)80149-9. [DOI] [PubMed] [Google Scholar]
  8. Carlson L. A., Olsson G., Ballantyne D. On the rise in low density and high density lipoproteins in response to the treatment of hypertriglyceridaemias in type IV and type V hyperlipoproteinaemias. Atherosclerosis. 1977 Apr;26(4):603–609. doi: 10.1016/0021-9150(77)90127-7. [DOI] [PubMed] [Google Scholar]
  9. Einarsson K., Hellström K., Leijd B. Bile acid kinetics and steroid balance during nicotinic acid therapy in patients with hyperlipoproteinemia types II and IV. J Lab Clin Med. 1977 Oct;90(4):613–622. [PubMed] [Google Scholar]
  10. Eisalo A., Manninen V. A long-term trial of gemfibrozil in the treatment of hyperlipidaemias. Proc R Soc Med. 1976;69 (Suppl 2):49–52. [PMC free article] [PubMed] [Google Scholar]
  11. Eisalo A., Manninen V., Mälkönen M., Kuhlbäck B. Hypolipidaemic action of gemfibrozil in adult nephrotics. Proc R Soc Med. 1976;69 (Suppl 2):47–48. [PMC free article] [PubMed] [Google Scholar]
  12. Ekman R., Nilsson-Ehle P. Effects of apolipoproteins on lipoprotein lipase activity of human adipose tissue. Clin Chim Acta. 1975 Aug 18;63(1):29–35. doi: 10.1016/0009-8981(75)90374-5. [DOI] [PubMed] [Google Scholar]
  13. Felker T. E., Fainaru M., Hamilton R. L., Havel R. J. Secretion of the arginine-rich and A-I apolipoproteins by the isolated perfused rat liver. J Lipid Res. 1977 Jul;18(4):465–473. [PubMed] [Google Scholar]
  14. Fenderson R. W., Deutsch S., Menachemi E., Chin B., Samuel P. Effect of gemfibrozil on serum lipids in man. Angiology. 1982 Sep;33(9):581–593. doi: 10.1177/000331978203300904. [DOI] [PubMed] [Google Scholar]
  15. Fidge N., Nestel P., Ishikawa T., Reardon M., Billington T. Turnover of apoproteins A-I and A-II of high density lipoprotein and the relationship to other lipoproteins in normal and hyperlipidemic individuals. Metabolism. 1980 Jul;29(7):643–653. doi: 10.1016/0026-0495(80)90109-2. [DOI] [PubMed] [Google Scholar]
  16. Fielding C. J., Fielding P. E. Cholesterol transport between cells and body fluids. Role of plasma lipoproteins and the plasma cholesterol esterification system. Med Clin North Am. 1982 Mar;66(2):363–373. doi: 10.1016/s0025-7125(16)31425-0. [DOI] [PubMed] [Google Scholar]
  17. Fielding C. J., Fielding P. E. Evidence for a lipoprotein carrier in human plasma catalyzing sterol efflux from cultured fibroblasts and its relationship to lecithin:cholesterol acyltransferase. Proc Natl Acad Sci U S A. 1981 Jun;78(6):3911–3914. doi: 10.1073/pnas.78.6.3911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Fielding C. J., Fielding P. E. Purification and substrate specificity of lecithin-cholesterol acyl transferase from human plasma. FEBS Lett. 1971 Jul 8;15(5):355–358. doi: 10.1016/0014-5793(71)80333-2. [DOI] [PubMed] [Google Scholar]
  19. Glomset J. A. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res. 1968 Mar;9(2):155–167. [PubMed] [Google Scholar]
  20. Grundy S. M., Mok H. Y., Zech L., Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res. 1981 Jan;22(1):24–36. [PubMed] [Google Scholar]
  21. HAVEL R. J., EDER H. A., BRAGDON J. H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955 Sep;34(9):1345–1353. doi: 10.1172/JCI103182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Havel R. J., Kane J. P., Kashyap M. L. Interchange of apolipoproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man. J Clin Invest. 1973 Jan;52(1):32–38. doi: 10.1172/JCI107171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Huttunen J. K., Ehnholm C., Kekki M., Nikkilä E. A. Post-heparin plasma lipoprotein lipase and hepatic lipase in normal subjects and in patients with hypertriglyceridaemia: correlations to sex, age and various parameters of triglyceride metabolism. Clin Sci Mol Med. 1976 Apr;50(4):249–260. doi: 10.1042/cs0500249. [DOI] [PubMed] [Google Scholar]
  24. Imaizumi K., Fainaru M., Havel R. J. Composition of proteins of mesenteric lymph chylomicrons in the rat and alterations produced upon exposure of chylomicrons to blood serum and serum proteins. J Lipid Res. 1978 Aug;19(6):712–722. [PubMed] [Google Scholar]
  25. Johnson J. D., Taskinen M. R., Matsuoka N., Jackson R. L. Dansyl phosphatidylethanolamine-labeled very low density lipoproteins. A fluorescent probe for monitoring lipolysis. J Biol Chem. 1980 Apr 25;255(8):3461–3465. [PubMed] [Google Scholar]
  26. Johnson J. D., Taskinen M. R., Matsuoka N., Jackson R. L. On the mechanism of the lipoprotein lipase-induced fluorescence changes in dansyl phosphatidylethanolamine-labeled very low density lipoproteins. J Biol Chem. 1980 Apr 25;255(8):3466–3471. [PubMed] [Google Scholar]
  27. Kashyap M. L., Barnhart R. L., Srivastava L. S., Perisutti G., Allen C., Hogg E., Glueck C. J., Jackson R. L. Alimentary lipemia: plasma high-density lipoproteins and apolipoproteins CII and CIII in healthy subjects. Am J Clin Nutr. 1983 Feb;37(2):233–243. doi: 10.1093/ajcn/37.2.233. [DOI] [PubMed] [Google Scholar]
  28. Kashyap M. L., Barnhart R. L., Srivastava L. S., Perisutti G., Vink P., Allen C., Hogg E., Brady D., Glueck C. J., Jackson R. L. Effects of dietary carbohydrate and fat on plasma lipoproteins and apolipoproteins C-II and C-III in healthy men. J Lipid Res. 1982 Aug;23(6):877–886. [PubMed] [Google Scholar]
  29. Kashyap M. L., Hynd B. A., Robinson K. A rapid and simple method for measurement of total protein in very low density lipoproteins by the Lowry assay. J Lipid Res. 1980 May;21(4):491–495. [PubMed] [Google Scholar]
  30. Kashyap M. L., Hynd B. A., Robinson K., Gartside P. S. Abnormal preponderance of sialylated apolipoprotein CIII in triglyceride rich lipoproteins in type V hyperlipoproteinemia. Metabolism. 1981 Feb;30(2):111–118. doi: 10.1016/0026-0495(81)90158-x. [DOI] [PubMed] [Google Scholar]
  31. Kesäniemi Y. A., Grundy S. M. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. JAMA. 1984 May 4;251(17):2241–2246. doi: 10.1001/jama.1984.03340410049031. [DOI] [PubMed] [Google Scholar]
  32. Kibe A., Holzbach R. T., LaRusso N. F., Mao S. J. Inhibition of cholesterol crystal formation by apolipoproteins in supersaturated model bile. Science. 1984 Aug 3;225(4661):514–516. doi: 10.1126/science.6429856. [DOI] [PubMed] [Google Scholar]
  33. Kissebah A. H., Alfarsi S., Adams P. W., Seed M., Folkard J., Wynn V. Transport kinetics of plasma free fatty acid, very low density lipoprotein triglycerides and apoprotein in patients with endogenous hypertriglyceridaemia: effects of 2,2-dimethyl, 5(2, 5-xylyoxy) valeric acid therapy. Atherosclerosis. 1976 Jul-Aug;24(1-2):199–218. doi: 10.1016/0021-9150(76)90076-9. [DOI] [PubMed] [Google Scholar]
  34. Konttinen A., Kuisma I., Ralli R., Pohjola S., Ojala K. The effect of gemfibrozil on serum lipids in diabetic patients. Ann Clin Res. 1979 Dec;11(6):240–245. [PubMed] [Google Scholar]
  35. Krauss R. M., Levy R. I., Fredrickson D. S. Selective measurement of two lipase activities in postheparin plasma from normal subjects and patients with hyperlipoproteinemia. J Clin Invest. 1974 Nov;54(5):1107–1124. doi: 10.1172/JCI107855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  37. Laurell C. B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem. 1966 Apr;15(1):45–52. doi: 10.1016/0003-2697(66)90246-6. [DOI] [PubMed] [Google Scholar]
  38. Levy R. I., Brensike J. F., Epstein S. E., Kelsey S. F., Passamani E. R., Richardson J. M., Loh I. K., Stone N. J., Aldrich R. F., Battaglini J. W. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. Circulation. 1984 Feb;69(2):325–337. doi: 10.1161/01.cir.69.2.325. [DOI] [PubMed] [Google Scholar]
  39. Lewis J. E. Long-term use of gemfibrozil (Lopid) in the treatment of dyslipidemia. Angiology. 1982 Sep;33(9):603–612. doi: 10.1177/000331978203300906. [DOI] [PubMed] [Google Scholar]
  40. Manninen V., Mälkönen M., Eisalo A., Virtamo J., Tuomilehto J., Kuusisto P. Gemfibrozil in the treatment of dyslipidaemia. A 5-year follow-up study. Acta Med Scand Suppl. 1982;668:82–87. doi: 10.1111/j.0954-6820.1982.tb08526.x. [DOI] [PubMed] [Google Scholar]
  41. Marsh J. B. Apoproteins of the lipoproteins in a nonrecirculating perfusate of rat liver. J Lipid Res. 1976 Jan;17(1):85–89. [PubMed] [Google Scholar]
  42. Matsuoka N., Shirai K., Johnson J. D., Kashyap M. L., Srivastava L. S., Yamamura T., Yamamoto A., Saito Y., Kumagai A., Jackson R. L. Effects of apolipoprotein C-II (apoC-II) on the lipolysis of very low density lipoproteins from apoC-II deficient patients. Metabolism. 1981 Aug;30(8):818–824. doi: 10.1016/0026-0495(81)90029-9. [DOI] [PubMed] [Google Scholar]
  43. Mendoza S. G., Zerpa A., Carrasco H., Colmenares O., Rangel A., Gartside P. S., Kashyap M. L. Estradiol, testosterone, apolipoproteins, lipoprotein cholesterol, and lipolytic enzymes in men with premature myocardial infarction and angiographically assessed coronary occlusion. Artery. 1983;12(1):1–23. [PubMed] [Google Scholar]
  44. Nash D. T. Hyperlipoproteinemia, atherosclerosis and gemfibrozil. Angiology. 1982 Sep;33(9):594–602. doi: 10.1177/000331978203300905. [DOI] [PubMed] [Google Scholar]
  45. Nikkilä E. A., Ylikahri R., Huttunen J. K. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia. Proc R Soc Med. 1976;69 (Suppl 2):58–63. [PMC free article] [PubMed] [Google Scholar]
  46. Olsson A. G., Rössner S., Walldius G., Carlson L. A. Effect of gemfibrozil on lipoprotein concentrations in different types of hyperlipoproteinaemia. Proc R Soc Med. 1976;69 (Suppl 2):28–31. [PMC free article] [PubMed] [Google Scholar]
  47. Packard C. J., Stewart J. M., Third J. L., Morgan H. G., Lawrie T. D., Shepherd J. Effects of nicotinic acid therapy on high-density lipoprotein metabolism in type II and type IV hyperlipoproteinaemia. Biochim Biophys Acta. 1980 Apr 18;618(1):53–62. doi: 10.1016/0005-2760(80)90053-3. [DOI] [PubMed] [Google Scholar]
  48. Roeschlau P., Bernt E., Gruber W. Enzymatic determination of total cholesterol in serum. Z Klin Chem Klin Biochem. 1974 May;12(5):226–226. [PubMed] [Google Scholar]
  49. Saku K., Cedres C., McDonald B., Hynd B. A., Liu B. W., Srivastava L. S., Kashyap M. L. C-II anapolipoproteinemia and severe hypertriglyceridemia. Report of a rare case with absence of C-II apolipoprotein isoforms and review of the literature. Am J Med. 1984 Sep;77(3):457–462. doi: 10.1016/0002-9343(84)90102-5. [DOI] [PubMed] [Google Scholar]
  50. Saku K., Reddy G. S., Hynd B. A., Kashyap M. L. Renal handling of high-density lipoproteins by isolated perfused kidneys. Metabolism. 1984 May;33(5):432–438. doi: 10.1016/0026-0495(84)90143-4. [DOI] [PubMed] [Google Scholar]
  51. Sata T., Havel R. J., Jones A. L. Characterization of subfractions of triglyceride-rich lipoproteins separated by gel chromatography from blood plasma of normolipemic and hyperlipemic humans. J Lipid Res. 1972 Nov;13(6):757–768. [PubMed] [Google Scholar]
  52. Schaefer E. J., Zech L. A., Jenkins L. L., Bronzert T. J., Rubalcaba E. A., Lindgren F. T., Aamodt R. L., Brewer H. B., Jr Human apolipoprotein A-I and A-II metabolism. J Lipid Res. 1982 Aug;23(6):850–862. [PubMed] [Google Scholar]
  53. Schwartz C. C., Halloran L. G., Vlahcevic Z. R., Gregory D. H., Swell L. Preferential utilization of free cholesterol from high-density lipoproteins for biliary cholesterol secretion in man. Science. 1978 Apr 7;200(4337):62–64. doi: 10.1126/science.204996. [DOI] [PubMed] [Google Scholar]
  54. Sewell R. B., Mao S. J., Kawamoto T., LaRusso N. F. Apolipoproteins of high, low, and very low density lipoproteins in human bile. J Lipid Res. 1983 Apr;24(4):391–401. [PubMed] [Google Scholar]
  55. Shepherd J., Packard C. J., Patsch J. R., Gotto A. M., Jr, Taunton O. D. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest. 1979 May;63(5):858–867. doi: 10.1172/JCI109385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Soutar A. K., Garner C. W., Baker H. N., Sparrow J. T., Jackson R. L., Gotto A. M., Smith L. C. Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: cholesterol acyltransferase. Biochemistry. 1975 Jul 15;14(14):3057–3064. doi: 10.1021/bi00685a003. [DOI] [PubMed] [Google Scholar]
  57. Streja D. A. Triglyceride removal from very low density lipoproteins in vivo as a function of their triglyceride content. Atherosclerosis. 1979 Jan;32(1):57–67. doi: 10.1016/0021-9150(79)90147-3. [DOI] [PubMed] [Google Scholar]
  58. Taskinen M. R., Johnson J. D., Kashyap M. L., Shirai K., Glueck C. J., Jackson R. L. Catabolism of human very low density lipoproteins in vitro: a fluorescent phospholipid method for monitoring lipolysis. J Lipid Res. 1981 Feb;22(2):382–386. [PubMed] [Google Scholar]
  59. Taskinen M. R., Kashyap M. L., Srivastava L. S., Ashraf M., Johnson J. D., Perisutti G., Brady D., Glueck C. J., Jackson R. L. In vitro catabolism of human plasma very low density lipoproteins. Effects of VLDL concentration on the interconversion of high density lipoprotein subfractions. Atherosclerosis. 1982 Feb;41(2-3):381–394. doi: 10.1016/0021-9150(82)90202-7. [DOI] [PubMed] [Google Scholar]
  60. Wu A. L., Windmueller H. G. Relative contributions by liver and intestine to individual plasma apolipoproteins in the rat. J Biol Chem. 1979 Aug 10;254(15):7316–7322. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES